Futura Medical makes progress with topical erection gel
28th Jun 2021 10:02
(Sharecast News) - Pharmaceutical company Futura Medical updated the market on its topical erectile dysfunction (ED) treatment 'MED3000' on Monday, given it now had CE-mark approval in Europe for the treatment of ED in adult men.
Read moreThursday broker round-up
3rd Jun 2021 12:50
(Sharecast News) - Experian: RBC Capital Markets downgrades to underperform with a target price of 2,400p.
Read moreFutura Medical surges on EU approval for topical erection gel
30th Apr 2021 13:23
(Sharecast News) - Pharmaceutical company Futura Medical has received CE marking for its 'MED3000' erectile dysfunction gel, it announced on Friday.
Read moreFutura Medical gets FDA OK for confirmatory study of erectile dysfunction gel
22nd Mar 2021 08:12
(Sharecast News) - Futura Medical shares surged on Monday after the company said it had agreed with the US Food and Drug Administration on the protocol for a small confirmatory clinical study of its erectile dysfunction gel, MED3000.
Read moreFutura's topical erection gel recommended for EU approval
19th Mar 2021 12:26
(Sharecast News) - Pharmaceuticals company Futura Medical said on Friday that the relevant EU notified body has completed the review of its technical dossier for 'MED3000', with a recommendation to certificate MED3000 as a class 2B approved medical device.
Read moreFutura makes solid progress on approval for erection gel
8th Dec 2020 12:52
(Sharecast News) - Pharmaceutical company Futura Medical updated the market on regulatory processes and commercial activities for MED3000 - its topical gel formulation for treatment of erectile dysfunction (ED).
Read moreFutura Medical narrows losses as it progresses erectile treatment
16th Sep 2020 12:44
(Sharecast News) - Futura Medical reported a net loss of £1.06m in its first half on Wednesday, narrowing from a net loss of £4.46m year-on-year.
Read moreFutura Medical upbeat on cannabidiol gel lab work
4th Aug 2020 12:57
(Sharecast News) - Pharmaceutical company Futura Medical announced the completion of initial laboratory and optimisation work on a 'Dermasys' cannabidiol gel, dubbed 'CBD100', under the joint venture collaboration agreement with CBDerma Technology that was announced in September.
Read moreFutura makes good progress with topical erectile dysfunction treatment
24th Jun 2020 11:06
(Sharecast News) - Futura Medical updated the market on Wednesday, reporting that the impact of the Covid-19 pandemic on the company had been "limited" to date.
Read moreFutura files for second FDA meeting over erection gel
20th Apr 2020 16:09
(Sharecast News) - Futura Medical has filed for a further pre-submission meeting with the US Food and Drug Administration (FDA), it announced on Monday, following receipt of the complete and signed clinical study report for its phase 3 Study, 'FM57'.
Read moreFutura Medical sees 'good progress' despite regulatory delays
24th Jun 2019 09:27
(Sharecast News) - Pharmaceutical company Futura Medical told investors at its annual general meeting on Monday that it had continued to make "good progress" in developing and commercialising its pipeline of product opportunities despite regulatory delays to the advancement of its pain relief gel.
Read moreFutura Medical recruits 1,000 patients for erectile treatment trial
19th Jun 2019 09:58
(Sharecast News) - Pharmaceutical company Futura Medical announced the completion of patient recruitment for the first European phase 3 study of MED2005, 'FM57', on Wednesday, adding that it remained on track to deliver headline data by the end of 2019.
Read moreMonday broker round-up
17th Jun 2019 12:21
(Sharecast News) - Hammerson: Peel Hunt upgrades to add with a target price of 350p.
Read moreFutura Medical focused on 'excellent' developments as losses deepen
26th Sep 2018 16:14
(Sharecast News) - Pharmaceutical group Futura Medical on Wednesday reported an "excellent" first-half as it continued to make progress on the development of two of its main products.
Read moreFutura Medical signs license agreement with Thornton & Ross
10th Jan 2017 11:05
(ShareCast News) - Futura Medical, an AIM listed innovative healthcare company focused on transdermal technology, has signed a licensing agreement with Thornton & Ross for the commercialisation of TPR100, the company's novel diclofenac gel for pain relief. Thornton & Ross (T&R) is one of the largest
Read more